Paclitaxel and Carboplatin with or without Metformin Hydrochloride in Treating Patients with Stage III, IV, or Recurrent Endometrial Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeTrial IDs
Phase III, Phase IIBiomarker/Laboratory analysis, TreatmentActive18 and overGOG-0286B
NCI-2013-02284, NCT02065687

Trial Description

Summary

This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel and carboplatin is more effective with or without metformin hydrochloride in treating endometrial cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine if the addition of metformin (metformin hydrochloride) to the standard regimen of carboplatin and paclitaxel prolongs progression-free survival (PFS) in women with advanced or recurrent endometrial cancer. (Phase II)

II. To determine if the addition of metformin to the standard regimen of carboplatin and paclitaxel prolongs overall survival (OS) in the same population if a phase III study is conducted. Both clinical trials (Phase II and III) will utilize OS as a primary endpoint if a phase III trial is opened.

SECONDARY OBJECTIVES:

I. To estimate the proportion of patients with objective response (response rate [RR]) in the population of patients with measurable disease by treatment.

II. To estimate the duration of response in the population of patients with measurable disease who respond by treatment.

III. To estimate overall survival (OS) and relative hazards of death for each treatment arm if the study stops after the phase II trial is completed. If the study continues with a phase III clinical trial, then PFS will be a secondary endpoint.

IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.

V. To estimate possible differences in RR, PFS, OS, and toxicity rates for the treatment regimens by the patients’ level of obesity.

TERTIARY OBJECTIVES:

I. To test whether PIK3CA mutations/amplifications, PTEN mutations or PIK3R1/PIK3R2 mutations have a lower hazard of progression or death (PFS endpoint) among patients who are treated with metformin.

II. To test whether higher expression of MATE 2 is associated with a lower hazard of progression or death (PFS endpoint) among patients who are treated with metformin.

III. To explore the association of metabolic factors (i.e. body mass index [BMI], hip-to-waist ratio, diabetes status, hemoglobin A1c [HgbA1C], fasting insulin and glucose levels, homeostatic model assessment [HOMA] scores) with treatment response to metformin/paclitaxel/carboplatin, PFS, and OS.

IV. To test whether genomic profiles (i.e.PIK3CA mutations/amplifications, PTEN mutations or PIK3R1/PIK3R2 mutations) differ between the tumors of obese and non-obese endometrial cancer (EC) patients.

V. To correlate expression of key targets of the insulin/IGF-1/mTOR signaling pathway (p-IGF1R, p-S6 and p-4EBP-1) with treatment response to metformin/paclitaxel/carboplatin, PFS, OS and obesity status.

VI. To determine if the genetic variants of the metformin transporters correspond with treatment response to metformin/paclitaxel/carboplatin, PFS and OS.

VII. To estimate differences in physical functioning, physical activity, and fatigue between treatment arms.

VIII. To explore the association between metabolic factors (i.e., BMI, hip-to-waist ratio, diabetes status, HgbA1C, fasting insulin and glucose levels, HOMA scores) and physical functioning, physical activity, and fatigue.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride orally (PO) twice daily (BID) (approximately 10-12 hours apart ) on days 1-21 (once daily [QD] in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

In both arms, patients who achieve stable disease (SD) or partial response (PR) and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Eligibility Criteria

Inclusion Criteria:

Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma

Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible:

  • Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)

Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI

Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl

Platelets greater than or equal to 100,000/mcl

Creatinine less than 1.4 mg/dl

Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN

Alkaline phosphatase less than or equal to 2.5 x ULN

Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma

Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy

Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy

Patients must be able to swallow and retain orally-administered medication

Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study

Exclusion Criteria:

Patients must NOT be taking metformin or have been on metformin in the past 6 months

Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study

Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
Victoria Lin Bae-Jump, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

Warner King Huh
Ph: 205-934-0309

Warner King Huh
Principal Investigator

Arizona
Phoenix

Saint Joseph's Hospital and Medical Center

John Hall Farley
Ph: 877-602-4111

John Hall Farley
Principal Investigator

University of Arizona Cancer Center at Saint Joseph's

John Hall Farley
Ph: 877-602-4111

John Hall Farley
Principal Investigator

Tucson

Arizona Oncology Associates-West Orange Grove

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Arizona Oncology Associates-Wilmot

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

The University of Arizona Medical Center-University Campus

Setsuko Kuki Chambers
Ph: 520-626-9008

Setsuko Kuki Chambers
Principal Investigator

University of Arizona Cancer Center-North Campus

Setsuko Kuki Chambers
Ph: 520-626-9008

Setsuko Kuki Chambers
Principal Investigator

Arkansas
Little Rock

University of Arkansas for Medical Sciences

Kristin Kelley Zorn
Ph: 501-686-8274

Kristin Kelley Zorn
Principal Investigator

California
Concord

John Muir Medical Center-Concord Campus

Babak Edraki
Ph: 925-674-2580

Babak Edraki
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Michael T. McHale
Ph: 858-822-5354
Email: cancercto@ucsd.edu

Michael T. McHale
Principal Investigator

Los Angeles

Kaiser Permanente Los Angeles Medical Center

Scott E. Lentz
Ph: 626-564-3455

Scott E. Lentz
Principal Investigator

Los Angeles County-USC Medical Center

Huyen Q. Pham
Ph: 323-865-0451

Huyen Q. Pham
Principal Investigator

USC / Norris Comprehensive Cancer Center

Huyen Q. Pham
Ph: 323-865-0451

Huyen Q. Pham
Principal Investigator

Mountain View

Palo Alto Medical Foundation-Gynecologic Oncology

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Oakland

Kaiser Permanente-Oakland

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Orange

Saint Joseph Hospital - Orange

Leslie M. Randall
Ph: 877-827-8839
Email: ucstudy@uci.edu

Leslie M. Randall
Principal Investigator

UC Irvine Health/Chao Family Comprehensive Cancer Center

Krishnansu Sujata Tewari
Ph: 714-456-6191
Email: awallick@uci.edu

Krishnansu Sujata Tewari
Principal Investigator

Palo Alto

Palo Alto Medical Foundation Health Care

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Stanford Cancer Institute

Oliver Dorigo
Ph: 650-498-7061
Email: ccto-office@stanford.edu

Oliver Dorigo
Principal Investigator

Pasadena

Keck Medical Center of USC Pasadena

Huyen Q. Pham
Ph: 323-865-0451

Huyen Q. Pham
Principal Investigator

Roseville

Kaiser Permanente-Roseville

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sacramento

Kaiser Permanente - Sacramento

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

University of California Davis Comprehensive Cancer Center

Edwin Alexander Alvarez
Ph: 916-734-3089

Edwin Alexander Alvarez
Principal Investigator

San Francisco

California Pacific Medical Center-Pacific Campus

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Kaiser Permanente-San Francisco

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

San Francisco General Hospital

Lee-May Chen
Ph: 877-827-3222

Lee-May Chen
Principal Investigator

UCSF Medical Center-Mission Bay

Lee-May Chen
Ph: 877-827-3222

Lee-May Chen
Principal Investigator

UCSF Medical Center-Mount Zion

Lee-May Chen
Ph: 877-827-3222

Lee-May Chen
Principal Investigator

San Jose

Kaiser Permanente-Santa Teresa-San Jose

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

San Leandro

Kaiser Permanente San Leandro

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Santa Cruz

Palo Alto Medical Foundation-Santa Cruz

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

South San Francisco

Kaiser Permanente-South San Francisco

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sunnyvale

Palo Alto Medical Foundation-Sunnyvale

John K. Chan
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

John K. Chan
Principal Investigator

Vallejo

Kaiser Permanente-Vallejo

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Walnut Creek

John Muir Medical Center-Walnut Creek

Babak Edraki
Ph: 925-674-2580

Babak Edraki
Principal Investigator

Kaiser Permanente-Walnut Creek

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Colorado
Aurora

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Saketh Ram Guntupalli
Ph: 720-848-0650

Saketh Ram Guntupalli
Principal Investigator

Fort Collins

Poudre Valley Hospital

Saketh Ram Guntupalli
Ph: 720-848-0650

Saketh Ram Guntupalli
Principal Investigator

Connecticut
Hartford

Hartford Hospital

Amy Kirkpatrick Brown
Ph: 860-545-5363

Amy Kirkpatrick Brown
Principal Investigator

New Britain

The Hospital of Central Connecticut

Amy Kirkpatrick Brown
Ph: 860-545-5363

Amy Kirkpatrick Brown
Principal Investigator

New Haven

Yale University

Elena S. Ratner
Ph: 203-785-5702

Elena S. Ratner
Principal Investigator

Delaware
Newark

Christiana Care Health System-Christiana Hospital

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Helen F Graham Cancer Center

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Medical Oncology Hematology Consultants PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Regional Hematology and Oncology PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Wilmington

Christiana Care Health System-Wilmington Hospital

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Florida
Gainesville

University of Florida

Merry Jennifer Markham
Ph: 352-273-8675
Email: trials@cancer.ufl.edu

Merry Jennifer Markham
Principal Investigator

Orlando

Florida Hospital Orlando

James Erasmus Kendrick
Ph: 407-303-2090
Email: FH.Cancer.Research@flhosp.org

James Erasmus Kendrick
Principal Investigator

Sarasota

Sarasota Memorial Hospital

James Vincent Fiorica
Ph: 941-917-2225

James Vincent Fiorica
Principal Investigator

Georgia
Atlanta

Emory University Hospital Midtown

Namita Khanna
Ph: 404-778-1868

Namita Khanna
Principal Investigator

Emory University/Winship Cancer Institute

Namita Khanna
Ph: 404-778-1868

Namita Khanna
Principal Investigator

Northside Hospital

Guilherme Henrique C. Cantuaria
Ph: 404-303-3355
Email: clinicaltrials@northside.com

Guilherme Henrique C. Cantuaria
Principal Investigator

Gainesville

Northeast Georgia Medical Center

Andrew Emmons Green
Ph: 770-219-8800
Email: cancerpatient.navigator@nghs.com

Andrew Emmons Green
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

William Edward Richards
Ph: 800-622-6877

William Edward Richards
Principal Investigator

Hawaii
Aiea

Hawaii Oncology Inc-Pali Momi

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Pali Momi Medical Center

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Ewa Beach

The Cancer Center of Hawaii-Leeward

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Honolulu

Hawaii Cancer Care Inc-Liliha

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Hawaii Cancer Care Inc-POB II

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Hawaii Oncology Inc-Kuakini

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Kapiolani Medical Center for Women and Children

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Kuakini Medical Center

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Queen's Medical Center

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Straub Clinic and Hospital

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

The Cancer Center of Hawaii-Liliha

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

University of Hawaii Cancer Center

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Lihue

Wilcox Memorial Hospital and Kauai Medical Clinic

Michael Ethan Carney
Ph: 808-983-6090

Michael Ethan Carney
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Illinois
Aurora

Rush - Copley Medical Center

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Chicago

Northwestern University

Shohreh Shahabi
Ph: 312-695-1301
Email: cancer@northwestern.edu

Shohreh Shahabi
Principal Investigator

University of Chicago Comprehensive Cancer Center

John William Moroney
Email: jmoroney@bsd.uchicago.edu

John William Moroney
Principal Investigator

Danville

Carle on Vermilion

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Carle Physician Group-Effingham

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Evanston

NorthShore University HealthSystem-Evanston Hospital

Jean A. Hurteau
Ph: 847-570-2109

Jean A. Hurteau
Principal Investigator

Galesburg

Illinois CancerCare-Galesburg

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Geneva

Northwestern Medicine Cancer Center Delnor

LaToya J. Perry
Ph: 630-315-1918
Email: Claudine.Gamster@CadenceHealth.org

LaToya J. Perry
Principal Investigator

Glenview

NorthShore University HealthSystem-Glenbrook Hospital

Jean A. Hurteau
Ph: 847-570-2109

Jean A. Hurteau
Principal Investigator

Highland Park

NorthShore University HealthSystem-Highland Park Hospital

Jean A. Hurteau
Ph: 847-570-2109

Jean A. Hurteau
Principal Investigator

Hinsdale

Sudarshan K Sharma MD Limted-Gynecologic Oncology

Sudarshan K. Sharma
Ph: 630-856-6757

Sudarshan K. Sharma
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Mattoon

Carle Physician Group-Mattoon/Charleston

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

New Lenox

UC Comprehensive Cancer Center at Silver Cross

John William Moroney
Email: jmoroney@bsd.uchicago.edu

John William Moroney
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Skokie

North Shore Medical Center

Jean A. Hurteau
Ph: 847-570-2109

Jean A. Hurteau
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Swansea

Cancer Care Specialists of Illinois-Swansea

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Urbana

Carle Cancer Center

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

The Carle Foundation Hospital

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Warrenville

Northwestern Medicine Cancer Center Warrenville

LaToya J. Perry
Ph: 630-315-1918
Email: Claudine.Gamster@CadenceHealth.org

LaToya J. Perry
Principal Investigator

Yorkville

Rush-Copley Healthcare Center

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Indiana
Indianapolis

Indiana University/Melvin and Bren Simon Cancer Center

Kathy Durham Miller
Ph: 317-274-2552

Kathy Durham Miller
Principal Investigator

Saint Vincent Hospital and Health Care Center

Michael J. Callahan
Ph: 317-338-2194
Email: research@stvincent.org

Michael J. Callahan
Principal Investigator

Michigan City

Franciscan Saint Anthony Health-Michigan City

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Woodland Cancer Care Center

Maria T. Grosse-Perdekamp
Ph: 800-446-5532

Maria T. Grosse-Perdekamp
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Clive

Medical Oncology and Hematology Associates-West Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Des Moines

Medical Oncology and Hematology Associates-Laurel

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Iowa City

University of Iowa/Holden Comprehensive Cancer Center

David Paul Bender
Ph: 800-237-1225

David Paul Bender
Principal Investigator

Kentucky
Lexington

University of Kentucky/Markey Cancer Center

Frederick Rand Ueland
Ph: 859-257-3379

Frederick Rand Ueland
Principal Investigator

Louisiana
New Orleans

Ochsner Medical Center Jefferson

Richard Carl Kline
Ph: 888-562-4763

Richard Carl Kline
Principal Investigator

Maine
Scarborough

Maine Medical Center- Scarborough Campus

Christopher J. Darus
Ph: 207-885-7565

Christopher J. Darus
Principal Investigator

Maryland
Baltimore

Greater Baltimore Medical Center

Paul Celano
Ph: 443-849-3706

Paul Celano
Principal Investigator

Johns Hopkins University/Sidney Kimmel Cancer Center

Deborah Kay Armstrong
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Deborah Kay Armstrong
Principal Investigator

Sinai Hospital of Baltimore

Abbie L. Fields
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Abbie L. Fields
Principal Investigator

Bethesda

Walter Reed National Military Medical Center

William J. Lowery
Ph: 301-319-2100

William J. Lowery
Principal Investigator

Massachusetts
Boston

Beth Israel Deaconess Medical Center

Neil Stuart Horowitz
Ph: 617-724-5200

Neil Stuart Horowitz
Principal Investigator

Brigham and Women's Hospital

Neil Stuart Horowitz
Ph: 617-724-5200

Neil Stuart Horowitz
Principal Investigator

Dana-Farber Cancer Institute

Neil Stuart Horowitz
Ph: 617-724-5200

Neil Stuart Horowitz
Principal Investigator

Tufts Medical Center

Young Bae Kim
Ph: 617-636-5000
Email: ContactUsCancerCenter@TuftsMedicalCenter.org

Young Bae Kim
Principal Investigator

Springfield

Baystate Medical Center

James S. Hoffman
Ph: 413-794-3565
Email: tamara.wrenn@baystatehealth.org

James S. Hoffman
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

University of Michigan Comprehensive Cancer Center

Carolyn M. Johnston
Ph: 734-712-3456

Carolyn M. Johnston
Principal Investigator

Battle Creek

Bronson Battle Creek

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Dearborn

Beaumont Hospital-Dearborn

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Detroit

Wayne State University/Karmanos Cancer Institute

Robert Thomas Morris
Ph: 313-576-9363

Robert Thomas Morris
Principal Investigator

Escanaba

Green Bay Oncology - Escanaba

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Farmington Hills

Weisberg Cancer Treatment Center

Robert Thomas Morris
Ph: 313-576-9363

Robert Thomas Morris
Principal Investigator

Flint

Genesys Hurley Cancer Institute

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Hurley Medical Center

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Grand Rapids

Mercy Health Saint Mary's

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Spectrum Health at Butterworth Campus

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Iron Mountain

Green Bay Oncology - Iron Mountain

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Jackson

Allegiance Health

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Lansing

Sparrow Hospital

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Livonia

Saint Mary Mercy Hospital

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Muskegon

Mercy Health Mercy Campus

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Reed City

Spectrum Health Reed City Hospital

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Royal Oak

William Beaumont Hospital-Royal Oak

Jayson Bert Field
Ph: 248-551-7695

Jayson Bert Field
Principal Investigator

Saginaw

Saint Mary's of Michigan

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Traverse City

Munson Medical Center

Kathleen J. Yost
Ph: 616-391-1230
Email: crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator

Troy

William Beaumont Hospital - Troy

Jayson Bert Field
Ph: 248-551-7695

Jayson Bert Field
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

J. Rebecca Liu
Ph: 734-712-3456

J. Rebecca Liu
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Coon Rapids

Mercy Hospital

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

Edina

Fairview-Southdale Hospital

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

University of Minnesota/Masonic Cancer Center

Melissa A. Geller
Ph: 612-624-2620

Melissa A. Geller
Principal Investigator

Rochester

Mayo Clinic

Jamie Nadine Bakkum-Gamez
Ph: 855-776-0015

Jamie Nadine Bakkum-Gamez
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

Saint Paul

United Hospital

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

Stillwater

Lakeview Hospital

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

Woodbury

Minnesota Oncology Hematology PA-Woodbury

Rachel E. Lerner
Ph: 952-993-1517
Email: mmcorc@parknicollet.com

Rachel E. Lerner
Principal Investigator

Mississippi
Jackson

Saint Dominic-Jackson Memorial Hospital

Donald Paul Seago
Ph: 601-200-3300

Donald Paul Seago
Principal Investigator

University of Mississippi Medical Center

James Tate Thigpen
Ph: 601-815-6700

James Tate Thigpen
Principal Investigator

Missouri
Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint John's Clinic-Rolla-Cancer and Hematology

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Barnes-Jewish Hospital

David Gardner Mutch
Ph: 800-600-3606
Email: info@ccadmin.wustl.edu

David Gardner Mutch
Principal Investigator

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Washington University School of Medicine

David Gardner Mutch
Ph: 800-600-3606
Email: info@ccadmin.wustl.edu

David Gardner Mutch
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Omaha

Nebraska Methodist Hospital

Peter Craig Morris
Ph: 402-354-7939
Email: kathryn.bartz@nmhs.org

Peter Craig Morris
Principal Investigator

Nevada
Las Vegas

Women's Cancer Center of Nevada

Nicola M. Spirtos
Ph: 702-851-4672

Nicola M. Spirtos
Principal Investigator

Reno

Center of Hope at Renown Medical Center

Peter Christopher-Why Lim
Ph: 866-513-8227

Peter Christopher-Why Lim
Principal Investigator

Renown Regional Medical Center

Peter Christopher-Why Lim
Ph: 866-513-8227

Peter Christopher-Why Lim
Principal Investigator

New Hampshire
Dover

Wentworth-Douglass Hospital

John Orland Schorge
Ph: 877-726-5130

John Orland Schorge
Principal Investigator

Lebanon

Dartmouth Hitchcock Medical Center

Leslie R. DeMars
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Leslie R. DeMars
Principal Investigator

New Jersey
Morristown

Morristown Medical Center

Paul B. Heller
Ph: 973-971-5900

Paul B. Heller
Principal Investigator

Mount Holly

Virtua Memorial

Randolph Bruce Deger
Ph: 609-914-6762

Randolph Bruce Deger
Principal Investigator

Voorhees

Virtua Voorhees

Randolph Bruce Deger
Ph: 609-914-6762

Randolph Bruce Deger
Principal Investigator

New York
Albany

Women's Cancer Care Associates LLC

Daniel Casey Kredentser
Ph: 518-458-1390

Daniel Casey Kredentser
Principal Investigator

Brooklyn

The New York Methodist Hospital

Katherine Economos
Ph: 718-780-5240

Katherine Economos
Principal Investigator

Buffalo

Roswell Park Cancer Institute

Shashikant B. Lele
Ph: 877-275-7724

Shashikant B. Lele
Principal Investigator

Mineola

Winthrop University Hospital

Eva Chalas
Ph: 866-946-8476

Eva Chalas
Principal Investigator

New York

Columbia University/Herbert Irving Cancer Center

Thomas J. Herzog
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Thomas J. Herzog
Principal Investigator

Mount Sinai Medical Center

Monica Prasad Hayes
Ph: 212-824-7320
Email: jenny.figueroa@mssm.edu

Monica Prasad Hayes
Principal Investigator

North Carolina
Charlotte

Novant Health Presbyterian Medical Center

John Matthew McDonald
Ph: 704-384-5369

John Matthew McDonald
Principal Investigator

Durham

Duke University Medical Center

Angeles Alvarez Secord
Ph: 888-275-3853

Angeles Alvarez Secord
Principal Investigator

Kernersville

Novant Health Oncology Specialists-Kernersville

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

Lexington

Novant Health Oncology Specialists-Davidson County

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

Mount Airy

Novant Health Oncology Specialists-Mount Airy

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

Pinehurst

FirstHealth of the Carolinas-Moore Regional Hosiptal

Michael John Sundborg
Ph: 910-692-7928

Michael John Sundborg
Principal Investigator

Raleigh

Duke Raleigh Hospital

Angeles Alvarez Secord
Ph: 888-275-3853

Angeles Alvarez Secord
Principal Investigator

Stateville

Novant Health Oncology Specialists-Statesville

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

Wilkesboro

Novant Health Oncology Specialists-Wilkesboro

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

Wilmington

New Hanover Regional Medical Center/Zimmer Cancer Center

Walter H. Gajewski
Ph: 910-342-3000

Walter H. Gajewski
Principal Investigator

Winston-Salem

Novant Health Oncology Specialists

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

Winston-Salem Health Care

Judith Owen Hopkins
Ph: 336-277-8887

Judith Owen Hopkins
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Fargo

Roger Maris Cancer Center

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Sanford Clinic North-Fargo

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Sanford Medical Center-Fargo

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Ohio
Akron

Summa Akron City Hospital/Cooper Cancer Center

Stephen J. Andrews
Ph: 330-375-6101

Stephen J. Andrews
Principal Investigator

Cincinnati

Bethesda North Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Good Samaritan Hospital - Cincinnati

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

University of Cincinnati

Thomas J. A. Reid
Ph: 937-298-3399
Email: som_dcop@wright.edu

Thomas J. A. Reid
Principal Investigator

Cleveland

Case Western Reserve University

Steven E. Waggoner
Ph: 800-641-2422

Steven E. Waggoner
Principal Investigator

Cleveland Clinic Cancer Center/Fairview Hospital

Peter G. Rose
Ph: 866-223-8100

Peter G. Rose
Principal Investigator

Cleveland Clinic Foundation

Peter G. Rose
Ph: 866-223-8100

Peter G. Rose
Principal Investigator

Columbus

Ohio State University Comprehensive Cancer Center

David M. O'Malley
Ph: 800-293-5066
Email: Jamesline@osumc.edu

David M. O'Malley
Principal Investigator

Riverside Methodist Hospital

Timothy David Moore
Ph: 614-488-2745
Email: sheree@columbusccop.org

Timothy David Moore
Principal Investigator

The Mark H Zangmeister Center

Timothy David Moore
Ph: 614-488-2745
Email: sheree@columbusccop.org

Timothy David Moore
Principal Investigator

Dayton

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350
Email: som_dcop@wright.edu

Howard M. Gross
Principal Investigator

Grandview Hospital

Eric Lawrence Eisenhauer
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Eric Lawrence Eisenhauer
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350
Email: som_dcop@wright.edu

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350
Email: som_dcop@wright.edu

Howard M. Gross
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

Peter G. Rose
Ph: 866-223-8100

Peter G. Rose
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Steven E. Waggoner
Ph: 800-641-2422

Steven E. Waggoner
Principal Investigator

Wright-Patterson Afb

Wright-Patterson Medical Center

Yovanni Casablanca
Ph: 937-775-1350
Email: som_dcop@wright.edu

Yovanni Casablanca
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Robert S. Mannel
Ph: 405-271-8777
Email: ou-clinical-trials@ouhsc.edu

Robert S. Mannel
Principal Investigator

Tulsa

Oklahoma Cancer Specialists and Research Institute-Tulsa

Robert S. Mannel
Ph: 405-271-8777
Email: ou-clinical-trials@ouhsc.edu

Robert S. Mannel
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Parviz Hanjani
Ph: 215-481-2402

Parviz Hanjani
Principal Investigator

Danville

Geisinger Medical Center

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Greensburg

UPMC Cancer Centers - Arnold Palmer Pavilion

Alexander Babatunde Olawaiye
Ph: 412-647-2811

Alexander Babatunde Olawaiye
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Lewisburg

Geisinger Medical Oncology-Lewisburg

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Lewistown

Lewistown Hospital

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Philadelphia

Thomas Jefferson University Hospital

Christine Heesun Kim
Ph: 215-955-6084

Christine Heesun Kim
Principal Investigator

University of Pennsylvania/Abramson Cancer Center

Robert Allen Burger
Ph: 215-746-7406

Robert Allen Burger
Principal Investigator

Pittsburgh

University of Pittsburgh Cancer Institute (UPCI)

Alexander Babatunde Olawaiye
Ph: 412-647-2811

Alexander Babatunde Olawaiye
Principal Investigator

UPMC-Magee Womens Hospital

Alexander Babatunde Olawaiye
Ph: 412-647-2811

Alexander Babatunde Olawaiye
Principal Investigator

UPMC-Passavant Hospital

Alexander Babatunde Olawaiye
Ph: 412-647-2811

Alexander Babatunde Olawaiye
Principal Investigator

Pottsville

Geisinger Medical Oncology-Pottsville

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Seneca

UPMC Cancer Center at UPMC Northwest

Alexander Babatunde Olawaiye
Ph: 412-647-2811

Alexander Babatunde Olawaiye
Principal Investigator

State College

Geisinger Medical Group

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Uniontown

UPMC Uniontown Hospital Radiation Oncology

Alexander Babatunde Olawaiye
Ph: 412-647-2811

Alexander Babatunde Olawaiye
Principal Investigator

West Chester

Chester County Hospital

William Emil Luginbuhl
Ph: 610-431-5297

William Emil Luginbuhl
Principal Investigator

West Reading

Reading Hospital

Bernice L. Robinson-Bennett
Ph: 610-988-9323

Bernice L. Robinson-Bennett
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Radhika P. Gogoi
Ph: 570-271-5251

Radhika P. Gogoi
Principal Investigator

Rhode Island
Providence

Women and Infants Hospital

Paul A. DiSilvestro
Ph: 401-274-1122

Paul A. DiSilvestro
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

Whitney Spannuth Graybill
Ph: 843-792-9321

Whitney Spannuth Graybill
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

David Griffin
Ph: 864-512-1000

David Griffin
Principal Investigator

Spartanburg

Spartanburg Medical Center

David Griffin
Ph: 864-512-1000

David Griffin
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Michael O. Robinson
Ph: 605-716-3982
Email: research@rcrh.org

Michael O. Robinson
Principal Investigator

Sioux Falls

Avera Cancer Institute

Luis A. Rojas-Espaillat
Ph: 888-634-7268
Email: oncregulatory@avera.org

Luis A. Rojas-Espaillat
Principal Investigator

Sanford Cancer Center-Oncology Clinic

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Sanford USD Medical Center - Sioux Falls

Maria Caroline Bell
Ph: 605-328-1368

Maria Caroline Bell
Principal Investigator

Tennessee
Chattanooga

Chattanooga's Program in Women's Oncology

Stephen Ernest DePasquale
Ph: 423-266-3636

Stephen Ernest DePasquale
Principal Investigator

Knoxville

University of Tennessee - Knoxville

Larry Clinton Kilgore
Ph: 865-544-9773

Larry Clinton Kilgore
Principal Investigator

Texas
Austin

Texas Oncology - Central Austin Cancer Center

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Texas Oncology - South Austin Cancer Center

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Texas Oncology-Austin Midtown

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

University Medical Center Brackenridge

James Stuart Ferriss
Ph: 215-728-2983

James Stuart Ferriss
Principal Investigator

Bedford

Texas Oncology Bedford

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Dallas

Texas Oncology at Baylor Charles A Sammons Cancer Center

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Fort Worth

Texas Oncology Fort Worth at 12th Avenue

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Houston

Lyndon Baines Johnson General Hospital

Lois M. Ramondetta
Ph: 713-792-3245

Lois M. Ramondetta
Principal Investigator

M D Anderson Cancer Center

Pamela Therese Soliman
Ph: 713-792-3245

Pamela Therese Soliman
Principal Investigator

Memorial Hermann Texas Medical Center

Joseph Anthony Lucci
Ph: 713-792-3245

Joseph Anthony Lucci
Principal Investigator

Longview

Texas Oncology-Longview Cancer Center

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Sugar Land

Texas Oncology Cancer Center Sugar Land

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

The Woodlands

Texas Oncology-The Woodlands

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Tyler

Tyler Cancer Center

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Webster

Deke Slayton Cancer Center

Michael A. Bookman
Ph: 520-269-3821

Michael A. Bookman
Principal Investigator

Utah
American Fork

American Fork Hospital / Huntsman Intermountain Cancer Center

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Cedar City

Sandra L Maxwell Cancer Center

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Logan

Logan Regional Hospital

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Murray

Intermountain Medical Center

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Ogden

McKay-Dee Hospital Center

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Provo

Utah Valley Regional Medical Center

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Saint George

Dixie Medical Center Regional Cancer Center

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

Theresa Louise Werner
Ph: 801-581-4477
Email: clinical.trials@hci.utah.edu

Theresa Louise Werner
Principal Investigator

LDS Hospital

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Utah Cancer Specialists-Salt Lake City

Xylina T. Gregg
Ph: 801-933-6070
Email: research@utahcancer.com

Xylina T. Gregg
Principal Investigator

Virginia
Charlottesville

University of Virginia Cancer Center

Susan Carnall Modesitt
Ph: 434-243-6322
Email: JME3D@hscmail.mcc.virginia.edu

Susan Carnall Modesitt
Principal Investigator

Richmond

Henrico Doctor's Hospital

William Patrick McGuire
Ph: 804-628-1939

William Patrick McGuire
Principal Investigator

Virginia Commonwealth University/Massey Cancer Center

William Patrick McGuire
Ph: 804-628-1939

William Patrick McGuire
Principal Investigator

Virginia Gynecologic Oncology

William Patrick McGuire
Ph: 804-628-1939

William Patrick McGuire
Principal Investigator

Roanoke

Carilion Clinic Gynecological Oncology

Janet L. Osborne
Ph: 540-985-8510

Janet L. Osborne
Principal Investigator

Washington
Burien

Highline Medical Center-Main Campus

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Gig Harbor

MultiCare Gig Harbor Medical Park

John A. Keech
Ph: 253-403-2394

John A. Keech
Principal Investigator

Seattle

Fred Hutchinson Cancer Research Center

Heidi Joy Gray
Ph: 206-616-8289

Heidi Joy Gray
Principal Investigator

Northwest Hospital

Heidi Joy Gray
Ph: 206-616-8289

Heidi Joy Gray
Principal Investigator

Seattle Cancer Care Alliance

Heidi Joy Gray
Ph: 206-616-8289

Heidi Joy Gray
Principal Investigator

University of Washington Medical Center

Heidi Joy Gray
Ph: 206-616-8289

Heidi Joy Gray
Principal Investigator

Women's Cancer Center of Seattle

Heidi Joy Gray
Ph: 206-616-8289

Heidi Joy Gray
Principal Investigator

Tacoma

Multicare Health System

John A. Keech
Ph: 253-403-2394

John A. Keech
Principal Investigator

MultiCare Tacoma General Hospital

John A. Keech
Ph: 253-403-2394

John A. Keech
Principal Investigator

West Virginia
Huntington

Edwards Comprehensive Cancer Center

Maria Rosalia B. Tria Tirona
Ph: 304-399-6617

Maria Rosalia B. Tria Tirona
Principal Investigator

Morgantown

Monongalia Hospital

Jamie L. Lesnock
Ph: 304-598-6560

Jamie L. Lesnock
Principal Investigator

Wisconsin
Green Bay

Green Bay Oncology at Saint Vincent Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Green Bay Oncology Limited at Saint Mary's Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

HSHS Saint Vincent Hospital Regional Cancer Center

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Saint Mary's Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Madison

University of Wisconsin Hospital and Clinics

Lisa Marie Barroilhet
Ph: 877-405-6866

Lisa Marie Barroilhet
Principal Investigator

Manitowoc

Holy Family Memorial Hospital

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Milwaukee

Froedtert and the Medical College of Wisconsin

William H. Bradley
Ph: 414-805-4380

William H. Bradley
Principal Investigator

Oconto Falls

Green Bay Oncology - Oconto Falls

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Sturgeon Bay

Green Bay Oncology - Sturgeon Bay

Jonathan Edward Tammela
Ph: 920-433-8889

Jonathan Edward Tammela
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT02065687

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.